DRUG vs. NVDA

Last updated Apr 1, 2026

Compare and contrast key facts about Bright Minds Biosciences Inc (DRUG) and NVIDIA Corporation (NVDA).

Performance

DRUG vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bright Minds Biosciences Inc (DRUG) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

DRUG vs. NVDA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DRUG Bright Minds Biosciences Inc	-6.50%	116.66%	2,418.88%	-61.35%	-76.66%	-41.30%
NVDA NVIDIA Corporation	-6.48%	38.92%	171.25%	239.02%	-50.26%	123.16%

Fundamentals

Market Cap DRUG : $566.34M NVDA : $4.26T
EPS DRUG : -$2.55 NVDA : $4.90
PB Ratio DRUG : 6.34 NVDA : 27.09
Total Revenue (TTM) DRUG : $0.00 NVDA : $215.94B
Gross Profit (TTM) DRUG : -$43.62K NVDA : $153.46B
EBITDA (TTM) DRUG : -$13.97M NVDA : $144.55B

Returns By Period

The year-to-date returns for both investments are quite close, with DRUG having a -6.50% return and NVDA slightly higher at -6.48%.

DRUG

• 1D: 6.60%
• 1M: -12.94%
• YTD: -6.50%
• 6M: 20.29%
• 1Y: 102.30%
• 3Y*: 221.27%
• 5Y*: 22.22%
• 10Y*: —

NVDA

• 1D: 5.59%
• 1M: -1.57%
• YTD: -6.48%
• 6M: -6.52%
• 1Y: 60.95%
• 3Y*: 84.54%
• 5Y*: 66.14%
• 10Y*: 69.61%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DRUG vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DRUG

DRUG Risk / Return Rank: 81
DRUG Sharpe Ratio Rank: 82
DRUG Sortino Ratio Rank: 83
DRUG Omega Ratio Rank: 75
DRUG Calmar Ratio Rank: 84
DRUG Martin Ratio Rank: 81

NVDA

NVDA Risk / Return Rank: 83
NVDA Sharpe Ratio Rank: 85
NVDA Sortino Ratio Rank: 82
NVDA Omega Ratio Rank: 80
NVDA Calmar Ratio Rank: 86
NVDA Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DRUG vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bright Minds Biosciences Inc (DRUG) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DRUG	NVDA	Difference
Sharpe ratio Return per unit of total volatility	1.39	1.48	-0.09
Sortino ratio Return per unit of downside risk	2.28	2.17	+0.11
Omega ratio Gain probability vs. loss probability	1.25	1.27	-0.03
Calmar ratio Return relative to maximum drawdown	2.81	2.92	-0.11
Martin ratio Return relative to average drawdown	6.29	7.39	-1.10
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DRUG vs. NVDA - Sharpe Ratio Comparison

The current DRUG Sharpe Ratio is 1.39, which is comparable to the NVDA Sharpe Ratio of 1.48. The chart below compares the historical Sharpe Ratios of DRUG and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DRUG	NVDA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.39	1.48	-0.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.03	1.29	-1.25
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.40	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	0.61	-0.58

Correlation

The correlation between DRUG and NVDA is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DRUG vs. NVDA - Dividend Comparison

DRUG has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.02%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
DRUG Bright Minds Biosciences Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVDA NVIDIA Corporation	0.02%	0.02%	0.03%	0.03%	0.11%	0.05%	0.12%	0.27%	0.46%	0.29%	0.45%	1.20%

Drawdowns

DRUG vs. NVDA - Drawdown Comparison

The maximum DRUG drawdown since its inception was -97.68%, which is greater than NVDA's maximum drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for DRUG and NVDA.

Drawdown Indicators

	DRUG	NVDA	Difference
Max Drawdown Largest peak-to-trough decline	-97.68%	-89.72%	-7.96%
Max Drawdown (1Y) Largest decline over 1 year	-35.56%	-20.21%	-15.35%
Max Drawdown (5Y) Largest decline over 5 years	-97.68%	-66.34%	-31.34%
Max Drawdown (10Y) Largest decline over 10 years	—	-66.34%	—
Current Drawdown Current decline from peak	-23.98%	-15.76%	-8.22%
Average Drawdown Average peak-to-trough decline	-60.66%	-36.40%	-24.26%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.89%	7.99%	+7.90%

Volatility

DRUG vs. NVDA - Volatility Comparison

Bright Minds Biosciences Inc (DRUG) has a higher volatility of 13.88% compared to NVIDIA Corporation (NVDA) at 10.46%. This indicates that DRUG's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DRUG	NVDA	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.88%	10.46%	+3.42%
Volatility (6M) Calculated over the trailing 6-month period	49.65%	25.91%	+23.74%
Volatility (1Y) Calculated over the trailing 1-year period	74.17%	41.44%	+32.73%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	662.78%	51.74%	+611.04%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	660.94%	49.85%	+611.09%

Financials